Sanofi Reports Results for Frexalimab in P-II Trial for the Treatment of Relapsing Multiple Sclerosis (MS)
Shots:
- The P-II trial evaluates frexalimab (1200/300mg with 1800/600mg loading dose, IV/SC, Q4W/Q2W) vs PBO in MS patients (n=52/51 vs 12/14). The 1EP was a reduction in the number of new GdE T1 MRI brain lesions at wk12 & 2EPs were efficacy, safety, tolerability & PK
- The results at wk12 depicted an 89% vs 79% reduction in new GdE T1 MRI brain lesions, 92% vs 86% reduction in new/enlarging T2-lesions & an 88% vs 80% reduction in the total number of GdE T1-lesions. The results from the trial were published in NEJM
- Following the 12wk analysis, patients receiving PBO were switched to receiving frexalimab in Part B of the study (ongoing). Frexalimab, an anti-CD4 Ab, functions by blocking the costimulatory CD40/CD40L pathway
Ref: Sanofi | Image: Sanofi
Related News:- Sanofi Highlights the Results for Nexviazyme (avalglucosidase alfa) in Clinical Evaluation for the Treatment of Pompe Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
